Rheum for Debate: Have biosimilars reduced drug costs for patients?
Click Here to Manage Email Alerts
Welcome to the first-ever Healio Rheum for Debate, in which we ask experts to take opposing sides and match wits on major topics in the field of rheumatology.
In this inaugural edition, Healio contributors and Healio Rheumatology Editorial Board members Allan Gibofsky, MD, JD, of Weill Medical College of Cornell University and the Hospital for Special Surgery, in New York, and John R.P. Tesser, MD, FACP, of Arizona Arthritis & Rheumatology Associates and Midwestern University, debated the topic of biosimilar cost and access for patients.
Specifically, we asked our participants to weigh in on the following question: Have biosimilars reduced the cost of medications for patients?
Dr. Tesser presented arguments on the side that biosimilars have, in fact, led to reduced medication cost for patients, while Dr. Gibofsky argued that biosimilars have not reduced cost for patients.
Each presenter had 7 minutes to make their case. A brief back-and-forth followed.
Collapse
Read more about
Click Here to Manage Email Alerts